MedicinemedRxiv
Ranked by formulaVerdict: NotableMulti-omic and Survival Analysis of Acute Chest Syndrome Burden in Sickle Cell Disease
Sickle cell disease (SCD) results from homozygosity or compound heterozygosity for a single point mutation in the beta hemoglobin gene.
Caveats
- Not randomized: its findings are associations.
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Sickle cell disease (SCD) results from homozygosity or compound heterozygosity for a single point mutation in the beta hemoglobin gene. Despite carrying the same underlying causal mutation, patients exhibit highly heterogeneous clinical outcomes. Acute chest syndrome (ACS) is one of the leading causes of mortality in SCD. In this study, we aimed to identify genetic variants associated with ACS occurrence and recurrence (>5 episodes) in two SCD cohorts (OMG-SCD and Walk-PHaSST) of predominantly African ancestry and characterize their downstream molecular consequences. Although none of the SNPs reached the genome-wide threshold in the occurrence meta-analysis, we identified 40 independent genetic loci with p 5 episodes, identified one genome-wide significant locus along with 38 other independent loci with p <10-5. Survival analysis suggested lower survival probability among young ACS recurrence cases compared to controls or occurrence cases. Furthermore, molecular QTL analysis of ACS recurrence identified 42 SNP-protein and eight SNP-metabolite associations with p <10-3. Pathway and enrichment analysis identified secretory, platelet/hemostatic, and complement-mediated pathways, confirming the complex and heterogeneous pathophysiology of ACS. This study highlights the importance of a well-defined phenotype for identification of risk loci and elucidates the complex interplay of hemolytic, inflammatory, and cellular organization pathways that warrants further evaluation through large-scale multi-omic studies of SCD patients. Ultimately, the more extreme phenotype of ACS recurrence may be a more informative phenotype for analysis, risk prediction, and therapeutic targeting.
The editor's rubric
- Leverage2 / 5
- Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
- Magnitude2 / 5
- Solid incremental gain on a meaningful problem.
- Evidence3 / 5
- Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
- Novelty2 / 5
- A new combination of known ideas.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes4 / 5
- Large-scale human impact: millions of people, or a major industry.
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: design (meta-analysis); verification (multiple benchmarks, independent replication); scale (scalable); stakes (mortality, major disease, prevention or cure). Red flags: not randomized.
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 5.6 / 10
- Adjusted merit
- 4.8 / 10
- Attention
- 0%
- Freshness
- 92%